Calcium-sensing soluble adenylyl cyclase mediates TNF signal transduction in human neutrophils

Through chemical screening, we identified a pyrazolone that reversibly blocked the activation of phagocyte oxidase (phox) in human neutrophils in response to tumor necrosis factor (TNF) or formylated peptide. The pyrazolone spared activation of phox by phorbol ester or bacteria, bacterial killing, T...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of experimental medicine Vol. 202; no. 3; pp. 353 - 361
Main Authors: Han, Hyunsil, Stessin, Alexander, Roberts, Julia, Hess, Kenneth, Gautam, Narinder, Kamenetsky, Margarita, Lou, Olivia, Hyde, Edward, Nathan, Noah, Muller, William A, Buck, Jochen, Levin, Lonny R, Nathan, Carl
Format: Journal Article
Language:English
Published: United States The Rockefeller University Press 01-08-2005
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Through chemical screening, we identified a pyrazolone that reversibly blocked the activation of phagocyte oxidase (phox) in human neutrophils in response to tumor necrosis factor (TNF) or formylated peptide. The pyrazolone spared activation of phox by phorbol ester or bacteria, bacterial killing, TNF-induced granule exocytosis and phox assembly, and endothelial transmigration. We traced the pyrazolone's mechanism of action to inhibition of TNF-induced intracellular Ca2+ elevations, and identified a nontransmembrane ("soluble") adenylyl cyclase (sAC) in neutrophils as a Ca2+-sensing source of cAMP. A sAC inhibitor mimicked the pyrazolone's effect on phox. Both compounds blocked TNF-induced activation of Rap1A, a phox-associated guanosine triphosphatase that is regulated by cAMP. Thus, TNF turns on phox through a Ca2+-triggered, sAC-dependent process that may involve activation of Rap1A. This pathway may offer opportunities to suppress oxidative damage during inflammation without blocking antimicrobial function.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
CORRESPONDENCE Carl Nathan: cnathan@med.cornell.edu OR Jochen Buck: jobuck@med.cornell.edu
ISSN:0022-1007
1540-9538
1892-1007
DOI:10.1084/jem.20050778